Cellebrite DI (CLBT) Cash & Equivalents (2020 - 2025)

Cellebrite DI's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $124.5 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 35.06% year-over-year to $124.5 million; the TTM figure through Dec 2025 stood at $124.5 million (down 35.06% YoY), while the FY2025 annual figure was $124.5 million, down 34.33% from the prior year.
• Cash & Equivalents was $124.5 million for Q4 2025 at Cellebrite DI, down from $191.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $191.7 million in Q4 2024 to a low of $84.6 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $131.6 million across 5 years, with a median of $123.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 39.96% in 2022, then soared 116.23% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $146.0 million in 2021, then tumbled by 39.96% to $87.6 million in 2022, then jumped by 116.23% to $189.5 million in 2023, then increased by 1.13% to $191.7 million in 2024, then sank by 35.06% to $124.5 million in 2025.
• The last three Cash & Equivalents figures came in at $124.5 million (Q4 2025), $191.7 million (Q3 2025), and $191.7 million (Q2 2025), per Business Quant data.